Related Experiment Video
Updated: Apr 1, 2026

Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas
Claudine Piérard-Franchimont1,2, Trinh Hermanns-Lê2, Philippe Paquet2
1Laboratory of Skin Bioengineering & Imaging (LABIC), Department of Clinical Sciences, University of Liège, Belgium.
Abstract:
Basal cell carcinomas (BCCs) are the most frequent human cancer. Over 90% of all BCCs have a mutation in PTCH1 or smoothened, two conducting proteins of the Hedgehog pathway. They rarely progress deeply and metastasize; however, if they do, these advanced basal cell carcinoma become amenable to treatment by inhibiting the Hedgehog and the P13K-mTOR pathways. Such innovative drugs include vismodegib, cyclopamine, itraconazole, everolimus and a few other agents that are in early clinical development.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway

